Healthcare Services

Chronic Plaque Psoriasis Market Forecast 2026–2035 Reflecting Expansion Opportunities Across Industries

March 31, 2026April 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Chronic Plaque Psoriasis Market Evolve From 2026 To 2030?

The market size for chronic plaque psoriasis has demonstrated substantial growth over recent years. Projections indicate an increase from $22.26 billion in 2025 to $23.83 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.1%. Historically, this market expansion can be attributed to several factors including improved diagnosis of autoimmune skin disorders, wider availability of topical therapies, increased awareness of psoriasis management, expansion of dermatology clinics, and improved access to specialty drugs.

The chronic plaque psoriasis market is projected to experience substantial expansion over the upcoming years. By 2030, its size is anticipated to reach $30.99 billion, exhibiting a compound annual growth rate (CAGR) of 6.8%. This projected growth during the forecast period stems from factors such as the accelerated development of next-generation biologics, the increasing embrace of oral immunomodulators, the broader application of precision dermatology strategies, a heightened emphasis on patient-centric treatment approaches, and a greater commitment to investment in autoimmune disease research. Key trends anticipated within the forecast period encompass a surge in the adoption of biologic therapies, an increased utilization of targeted small molecule drugs, a strengthening focus on personalized dermatology care, an expansion in available oral treatment options, and a reinforced commitment to achieving long-term disease control.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20726&type=smp

What Key Drivers Are Influencing The Growth Of The Chronic Plaque Psoriasis Market?

The expanding incidence of immune system dysfunction is anticipated to fuel the future expansion of the chronic plaque psoriasis market. Immune system dysfunction describes a condition where the immune system does not function properly, increasing vulnerability to infections, autoimmune disorders, and cancer. A growing number of immune system dysfunction cases stem from factors like genetic susceptibility, environmental irritants, poor nutrition, prolonged stress, and the increasing occurrence of autoimmune conditions and infections such as HIV. Treatment for chronic plaque psoriasis is necessary to manage immune system dysfunction, given that the immune system erroneously stimulates excessive skin cell production, resulting in inflammation and plaque development. For example, as reported in February 2024 by Arthritis Australia, an Australia-based non-profit organization, in 2025, approximately 212,136 males and 362,137 females are estimated to be affected by rheumatoid arthritis (RA), with these figures anticipated to climb by 2040 to around 280,040 males and 479,828 females. Consequently, the rising instances of immune system dysfunction are fueling the expansion of the chronic plaque psoriasis market.

Which Segment Areas Are Covered In The Chronic Plaque Psoriasis Market Analysis?

The chronic plaque psoriasis market covered in this report is segmented –

1) By Drug Class: Biologics, Small Molecule Drugs

2) By Route Of Administration: Injectable, Oral, Topical

3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

Subsegments:

1) By Biologics: Tumor Necrosis Factor (TNF) Inhibitors, Interleukin Inhibitors (IL-12, IL-23, IL-17, IL-22), T-Cell Inhibitors

2) By Small Molecule Drugs: Phosphodiesterase 4 (PDE4) Inhibitors, Janus Kinase (JAK) Inhibitors, Retinoids

How Are Trends Transforming The Chronic Plaque Psoriasis Market Landscape?

Major companies in the chronic plaque psoriasis market are prioritizing the development of innovative treatments, such as IL-17A and IL-17F inhibitors, to enhance therapeutic options for chronic plaque psoriasis. IL-17A and IL-17F inhibitors are targeted biologic therapies that work by blocking interleukin-17A and interleukin-17F, which are pro-inflammatory cytokines involved in the immune response, thereby reducing inflammation in autoimmune diseases like chronic plaque psoriasis. For instance, in October 2023, UCB S.A., a Belgium-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved BIMZELX (bimekizumab-bkzx) for adults with moderate to severe plaque psoriasis eligible for systemic therapy or phototherapy. Bimekizumab is the first approved medication for psoriasis specifically designed to target and inhibit interleukin 17A (IL-17A) and interleukin 17F (IL-17F), two key cytokines implicated in inflammatory processes. Its approval was founded on data from three Phase 3 multicenter trials—BE READY, BE VIVID, and BE SURE—which together assessed its safety and efficacy in 1,480 patients with moderate to severe plaque psoriasis.

Which Global Companies Are Actively Competing In The Chronic Plaque Psoriasis Market?

Major companies operating in the chronic plaque psoriasis market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, Amgen Inc., Dr Reddy’s Laboratories, Innovent Biologics Inc., Bio-Thera Solutions, Celgene Corporation, Arcutis Biotherapeutics, LEO Pharma A/S, Sun Pharmaceutical Industries Ltd, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Biocon Ltd, Stiefel Laboratories Inc, Regeneron Pharmaceuticals, Sanofi S.A., GSK plc, Merck & Co. Inc., UCB S.A., Roche Holding AG, Evelo Biosciences Inc, Biogen Inc.

Read the full chronic plaque psoriasis market report here:

https://www.thebusinessresearchcompany.com/report/chronic-plaque-psoriasis-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Chronic Plaque Psoriasis Market?

North America was the largest region in the chronic plaque psoriasis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic plaque psoriasis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Chronic Plaque Psoriasis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20726&type=smp

Browse Through More Reports Similar to the Global Chronic Plaque Psoriasis Market 2026, By The Business Research Company

Pancreatic Cancer Diagnostic Global Market Report

https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report

Exocrine Pancreatic Insufficiency Global Market Report

https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-global-market-report

Invasive Ductal Carcinoma Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/invasive-ductal-carcinoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795